Internal Medicine, Endocrinology, Diabetes, & Metabolism · Trumbull, CT
NPI
1568421469
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
112 Quarry Rd, Suite 250
Trumbull, CT, 06611
Phone (203) 374-6162
Groups this clinician bills Medicare through
Medicare paid, 2024
$87K
2,638 services
Medicare patients, 2024
243
Average age 75
Drug cost, 2024
$3.8M
7,778 prescriptions
Company payments, 2025
$517
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joseph A Rosa was code 99214 (office e&m - established), 557 times for 223 patients. In total Joseph A Rosa billed 2,638 services in 14 codes, and Medicare paid $87K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-01-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 557 | 223 | $98.22 | $55K |
| 82962 Clinical Chemistry | Office | 543 | 198 | $3.21 | $1,743 |
| 83037 Blood Count | Office | 270 | 162 | $9.52 | $2,570 |
| 83036 Blood Count | Office | 154 | 133 | $9.52 | $1,466 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 119 | 95 | $13.99 | $1,665 |
| 99213 Office E&M - Established | Office | 86 | 71 | $57.11 | $4,911 |
| 95251 Test - Miscellaneous | Office | 64 | 41 | $25.59 | $1,638 |
| G0108 Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 21 | 12 | $47.51 | $998 |
| 95249 Test - Miscellaneous | Office | 13 | 12 | $59.11 | $768 |
By year: 2022 $84K for 2,413 services; 2023 $78K for 2,371 services; 2024 $87K for 2,638 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 543 | 198 | $3.21 | $1,743 |
| 83037 Blood Count | 270 | 162 | $9.52 | $2,570 |
| 83036 Blood Count | 154 | 133 | $9.52 | $1,466 |
Medicare prescription drug claims, 2024
In 2024, the drug Joseph A Rosa prescribed most often to Medicare patients was Ozempic (Semaglutide), with 415 prescriptions and refills. In total Joseph A Rosa wrote 7,778 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 415 | 744 | 110 | $716K |
| Levothyroxine Sodium Generic | 379 | 1,053 | 111 | $7,034 |
| Jardiance Empagliflozin | 318 | 705 | 94 | $413K |
| Glipizide Generic | 297 | 790 | 85 | $3,167 |
| Mounjaro Tirzepatide | 283 | 417 | 57 | $452K |
| Tresiba Flextouch U-100 Insulin Degludec | 265 | 691 | 89 | $174K |
| Synthroid Levothyroxine Sodium | 264 | 712 | 77 | $31K |
| Tresiba Flextouch U-200 Insulin Degludec | 246 | 650 | 76 | $293K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 234 | 493 | 90 | $22K |
| Rosuvastatin Calcium Generic | 217 | 605 | 71 | $2,931 |
| Metformin Hcl Generic | 178 | 508 | 55 | $1,182 |
| Novolog Mix 70-30 Flexpen Insulin Aspart Prot/Insuln Asp | 162 | 301 | 36 | $35K |
| Atorvastatin Calcium Generic | 158 | 409 | 48 | $1,257 |
| Januvia Sitagliptin Phosphate | 156 | 348 | 36 | $189K |
| Lisinopril Generic | 138 | 370 | 40 | $1,007 |
Brand drugs: 4,006 claims; generic drugs: 3,135 claims; opioid claims: 17.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joseph A Rosa $517 ($517 in general payments such as food, travel and fees) from 2 companies. The largest payer was Abbott Laboratories with $395.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 21 | $395 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $122 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.